411 related articles for article (PubMed ID: 36107200)
1. Nanomedicine and drug delivery to the retina: current status and implications for gene therapy.
Tawfik M; Chen F; Goldberg JL; Sabel BA
Naunyn Schmiedebergs Arch Pharmacol; 2022 Dec; 395(12):1477-1507. PubMed ID: 36107200
[TBL] [Abstract][Full Text] [Related]
2. Nanotechnology in retinal drug delivery.
Jiang S; Franco YL; Zhou Y; Chen J
Int J Ophthalmol; 2018; 11(6):1038-1044. PubMed ID: 29977820
[TBL] [Abstract][Full Text] [Related]
3. Ocular Drug Delivery: Present Innovations and Future Challenges.
Gote V; Sikder S; Sicotte J; Pal D
J Pharmacol Exp Ther; 2019 Sep; 370(3):602-624. PubMed ID: 31072813
[TBL] [Abstract][Full Text] [Related]
4. Nanomedicines for back of the eye drug delivery, gene delivery, and imaging.
Kompella UB; Amrite AC; Pacha Ravi R; Durazo SA
Prog Retin Eye Res; 2013 Sep; 36():172-98. PubMed ID: 23603534
[TBL] [Abstract][Full Text] [Related]
5. Nanotechnology approaches for ocular drug delivery.
Xu Q; Kambhampati SP; Kannan RM
Middle East Afr J Ophthalmol; 2013; 20(1):26-37. PubMed ID: 23580849
[TBL] [Abstract][Full Text] [Related]
6. Nanocarrier mediated retinal drug delivery: overcoming ocular barriers to treat posterior eye diseases.
Bisht R; Mandal A; Jaiswal JK; Rupenthal ID
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2018 Mar; 10(2):. PubMed ID: 28425224
[TBL] [Abstract][Full Text] [Related]
7. [Novel approach for management of age-related macular degeneration--antiangiogenic therapy and retinal regenerative therapy].
Tamaki Y
Nippon Ganka Gakkai Zasshi; 2007 Mar; 111(3):232-68; discussion 269. PubMed ID: 17402564
[TBL] [Abstract][Full Text] [Related]
8. A new era in posterior segment ocular drug delivery: Translation of systemic, cell-targeted, dendrimer-based therapies.
Kannan RM; Pitha I; Parikh KS
Adv Drug Deliv Rev; 2023 Sep; 200():115005. PubMed ID: 37419213
[TBL] [Abstract][Full Text] [Related]
9. Nanoengineering of therapeutics for retinal vascular disease.
Gahlaut N; Suarez S; Uddin MI; Gordon AY; Evans SM; Jayagopal A
Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):323-30. PubMed ID: 26022642
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal therapeutic nanoparticles for age-related macular degeneration: Design principles, progress and opportunities.
Zhang Y; Watson S; Ramaswamy Y; Singh G
Adv Colloid Interface Sci; 2024 Jul; 329():103200. PubMed ID: 38788306
[TBL] [Abstract][Full Text] [Related]
11. Nanoparticulate Drug Delivery to the Retina.
Li Q; Weng J; Wong SN; Thomas Lee WY; Chow SF
Mol Pharm; 2021 Feb; 18(2):506-521. PubMed ID: 32501716
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal hydrogels for sustained release of therapeutic proteins.
Ilochonwu BC; Urtti A; Hennink WE; Vermonden T
J Control Release; 2020 Oct; 326():419-441. PubMed ID: 32717302
[TBL] [Abstract][Full Text] [Related]
13. Dexamethasone - PAMAM dendrimer conjugates for retinal delivery: preparation, characterization and in vivo evaluation.
Yavuz B; Bozdağ Pehlivan S; Sümer Bolu B; Nomak Sanyal R; Vural İ; Ünlü N
J Pharm Pharmacol; 2016 Aug; 68(8):1010-20. PubMed ID: 27283886
[TBL] [Abstract][Full Text] [Related]
14. Posterior segment drug delivery for the treatment of exudative age-related macular degeneration and diabetic macular oedema.
Wong CW; Wong TT
Br J Ophthalmol; 2019 Oct; 103(10):1356-1360. PubMed ID: 31040133
[TBL] [Abstract][Full Text] [Related]
15. Drug delivery to the posterior segment of the eye.
Thrimawithana TR; Young S; Bunt CR; Green C; Alany RG
Drug Discov Today; 2011 Mar; 16(5-6):270-7. PubMed ID: 21167306
[TBL] [Abstract][Full Text] [Related]
16. Liposomes and nanotechnology in drug development: focus on ocular targets.
Honda M; Asai T; Oku N; Araki Y; Tanaka M; Ebihara N
Int J Nanomedicine; 2013; 8():495-503. PubMed ID: 23439842
[TBL] [Abstract][Full Text] [Related]
17. Biodegradable Polymer-Based Drug-Delivery Systems for Ocular Diseases.
Tsung TH; Tsai YC; Lee HP; Chen YH; Lu DW
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629157
[TBL] [Abstract][Full Text] [Related]
18. Nanoparticle-loaded biodegradable light-responsive in situ forming injectable implants for effective peptide delivery to the posterior segment of the eye.
Bisht R; Jaiswal JK; Rupenthal ID
Med Hypotheses; 2017 Jun; 103():5-9. PubMed ID: 28571808
[TBL] [Abstract][Full Text] [Related]
19. Emerging innovations in nano-enabled therapy against age-related macular degeneration: A paradigm shift.
Kumar Dubey S; Pradhan R; Hejmady S; Singhvi G; Choudhury H; Gorain B; Kesharwani P
Int J Pharm; 2021 May; 600():120499. PubMed ID: 33753164
[TBL] [Abstract][Full Text] [Related]
20. Nanotechnology in Retinal Disease: Current Concepts and Future Directions.
Mehta NJ; Mehta SN
J Ocul Pharmacol Ther; 2024; 40(1):3-12. PubMed ID: 38052063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
